Stockscreener 앱 받기
4.69
3.30%
-0.16
전일 마감가:
$4.85
열려 있는:
$5
하루 거래량:
795
Relative Volume:
0.00
시가총액:
$5.30M
수익:
-
순이익/손실:
$-36.46M
주가수익비율:
-1.9542
EPS:
-2.4
순현금흐름:
$-30.20M
1주 성능:
-4.48%
1개월 성능:
+90.65%
6개월 성능:
+146.19%
1년 성능:
-27.96%
1일 변동 폭
$5.00
$5.00
1주일 범위
$4.255
$5.4837
52주 변동 폭
$1.3137
$6.992
Alaunos Therapeutics Inc Stock (TCRT) Company Profile
명칭
Alaunos Therapeutics Inc
전화
(346) 355-4099
주소
2617 BISSONNET ST, HOUSTON
TCRT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TCRT
Alaunos Therapeutics Inc
|
5.00 | 5.30M | 0 | -36.46M | -30.20M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.83 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.21 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.46 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.60 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Alaunos Therapeutics Inc Stock (TCRT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-10-04 | 재개 | Wells Fargo | Overweight |
Alaunos Therapeutics Inc 주식(TCRT)의 최신 뉴스
PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies - The Manila Times
PMGC Capital Urges Alaunos Therapeutics to Accept Strategic Financing Opportunity - Nasdaq
PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) - GlobeNewswire
PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading - Bluefield Daily Telegraph
Clean Financing Deal: Top Wall Street Bank Backs Alaunos While Major Investor PMGC Capital Demands Action - Stock Titan
Alaunos Therapeutics Amends Warrant Agreement with Mast Hill - TipRanks
Alaunos Therapeutics Secures $25M Equity Purchase Deal - MSN
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Update - Defense World
Ziopharm: Q1 Earnings Snapshot - CT Insider
Alaunos Therapeutics (NASDAQ:TCRT) Trading Down 2.4% – Time to Sell? - Defense World
PMGC Capital announces filing to report 5.09% stake in Alaunos Therapeutics - TipRanks
PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. - GlobeNewswire
PMGC Capital Takes 5.09% Stake in Alaunos Therapeutics, Eyes Strategic Changes Including Fintech Expansion - Stock Titan
Alaunos Therapeutics (NASDAQ:TCRT) Trading Up 2.5% – Time to Buy? - Defense World
Alaunos Therapeutics announces board member resignation - Investing.com Australia
Alaunos Therapeutics announces board member resignation By Investing.com - Investing.com Canada
Form 8-KCurrent report - ADVFN
Alaunos Therapeutics Board Opts for Equity Compensation - TipRanks
Alaunos Therapeutics announces private placement of preferred stock By Investing.com - Investing.com Canada
Alaunos Therapeutics announces private placement of preferred stock - Investing.com
Alaunos Therapeutics And 2 Other Promising Penny Stocks To Watch - simplywall.st
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Down 12.5% in March - Defense World
11 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday SessionAllakos (NASDAQ:ALLK), Alumis (NASDAQ:ALMS) - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Alaunos Therapeutics Inc. (TCRT) reports earnings - Quartz
Alaunos Therapeutics (NASDAQ:TCRT) Shares Down 6.5% – Here’s What Happened - Defense World
Lantheus acquires radiopharma CDMO Evergreen for up to $1bn - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Up 4% – Should You Buy? - Defense World
Update: Johnson & Johnson acquires Intra-Cellular Therapies - Pharmaceutical Technology
Light Horse emerges with $62m and Novartis partnership worth up to $1bn - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Down 0.5% – Time to Sell? - Defense World
TCRT stock touches 52-week low at $1.92 amid market challenges - Investing.com
Novartis acquires Kate Therapeutics to advance gene therapies - Pharmaceutical Technology
Alaunos Therapeutics, Inc. SEC 10-Q Report - TradingView
Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy - Yahoo Finance
Precigen Terminates License Agreement With Alaunos Therapeutics - MarketWatch
Genentech buys Regor’s CDK inhibitors in $850m deal - Clinical Trials Arena
VION Biosciences acquires Echelon Biosciences - Pharmaceutical Technology
TCRT stock touches 52-week low at $2.28 amid market challenges - Investing.com India
Eli Lilly inaugurates R&D facility in Boston, US - Pharmaceutical Technology
Alaunos Therapeutics announces 1-for-10 reverse stock split - Investing.com
Avenzo Therapeutics secures $150m to bolster oncology pipeline - Pharmaceutical Technology
Gilead concludes acquisition of CymaBay Therapeutics for $4.3bn - Pharmaceutical Technology
Alaunos Therapeutics Announces 1-for-15 Reverse Stock Split - TipRanks
Kyowa Kirin acquires Orchard Therapeutics for $477.6m - Pharmaceutical Technology
NAYA buys gene therapy company Florida Biotech for $20m - Clinical Trials Arena
Genentech signs nanoparticle deal worth up to $644m with GenEdit - Pharmaceutical Technology
BridGene and Galapagos partner for oncology drugs discovery - Pharmaceutical Technology
Novartis allies with Voyager to develop gene therapies in $1.3bn deal - Pharmaceutical Technology
ELABPMGC Holdings Latest Stock News & Market Updates - Stock Titan
Alaunos Therapeutics Inc (TCRT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.21%
2.91%
자본화:
|
볼륨(24시간):